Rosacea, Hair Loss, and Skin Conditions: Diagnosis, Causes, and Treatment Options

What Is Rosacea and How Is It Diagnosed?

Rosacea is a chronic, relapsing inflammatory condition of the facial skin. The American Academy of Dermatology (AAD) 2019 clinical guidelines define four major subtypes: erythematotelangiectatic (ETR), papulopustular (PPR), phymatous, and ocular. Diagnosis is clinical, based on persistent centrofacial redness, telangiectasias, or papulopustular lesions lasting at least three months in the absence of other causes.

The Four Subtypes Explained

Erythematotelangiectatic rosacea (ETR) presents with flushing, persistent redness, and visible blood vessels across the nose and cheeks. Triggers include sun exposure, alcohol, hot beverages, and emotional stress. Skin may feel burning or stinging.

Papulopustular rosacea (PPR) resembles acne but lacks comedones. It responds well to topical agents. A 12-week randomized controlled trial (N=251) published in the Journal of the American Academy of Dermatology showed that topical metronidazole 1% cream reduced inflammatory lesion counts by 65% vs. 39% with vehicle.

Phymatous rosacea produces skin thickening, most often rhinophyma (bulbous nose). W.C. Fields-type nose enlargement is a classic example. Laser ablation or surgical debulking is often required at this stage.

Ocular rosacea causes eyelid inflammation, dry eye, and corneal involvement. The AAD guidelines recommend oral doxycycline 40 mg modified-release (Oracea) plus lid hygiene as first-line for ocular involvement.

First-Line and Second-Line Treatments for Rosacea

Topical agents form the foundation of rosacea treatment:

• Metronidazole 0.75% gel or 1% cream: applied once or twice daily for 12-16 weeks
• Azelaic acid 15% gel (Finacea): applied twice daily; showed 57% reduction in lesion count vs. 41% placebo in a 15-week RCT (N=664) published in JAAD
• Ivermectin 1% cream (Soolantra): once-daily application; in a 52-week investigator-blinded trial (N=962), ivermectin showed significantly greater lesion count reduction than metronidazole 0.75% at week 16 (P<0.001) (Taieb et al., NEJM Evidence, 2015)

Oral agents for moderate-to-severe PPR:

• Doxycycline 40 mg modified-release (Oracea): the only FDA-approved oral therapy for rosacea; one 40 mg capsule taken once daily in the morning at least 1 hour before eating
• Standard doxycycline 100 mg is off-label and carries higher risk of antibiotic resistance

Vascular and laser procedures for ETR and persistent erythema:

• Pulsed-dye laser (PDL) at 585-595 nm: reduces telangiectasias and background redness; sessions are typically 4-6 weeks apart
• Intense pulsed light (IPL): broad-spectrum 515-1,200 nm; comparable efficacy to PDL for diffuse redness per a split-face RCT (Papageorgiou et al., BJD, 2008)

Sun protection is non-negotiable. The AAD recommends broad-spectrum SPF 30 or higher applied daily, regardless of cloud cover, for all rosacea subtypes.

Male Pattern Hair Loss (Androgenetic Alopecia in Men)

Male pattern hair loss (MPHL) is the most common form of hair loss in men, driven by the conversion of testosterone to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase type II. DHT binds androgen receptors in genetically susceptible follicles, shortening the anagen (growth) phase and progressively miniaturizing hairs until follicles stop producing visible strands.

How Genetics and DHT Interact

The androgen receptor gene (AR) on the X chromosome carries a significant portion of hereditary risk, meaning a man's maternal grandfather's hairline offers some predictive value. However, the condition is polygenic. A genome-wide association study of 205,327 men identified 287 independent genetic signals associated with MPHL, published in PLOS Genetics. No single gene fully predicts outcome.

DHT levels in the scalp, rather than serum testosterone, are the proximate driver. This distinction matters clinically: a man with normal serum testosterone can still lose hair if scalp 5-alpha reductase activity is high.

FDA-Approved Drug Treatments

Finasteride 1 mg oral (Propecia): Inhibits 5-alpha reductase type II, reducing scalp DHT by approximately 60%. In the landmark Finasteride 1 mg Study Group RCT (N=1,553, Kaufman et al., JAAD 1998), 83% of men on finasteride showed no further hair loss at 24 months vs. 28% with placebo. Hair count increased by a mean of 107 hairs per square inch in the vertex region. Sexual side effects (libido changes, erectile dysfunction) occurred in approximately 2% of treated men vs. 1.3% placebo.

Minoxidil 2% and 5% topical solution (Rogaine): A potassium-channel opener that prolongs the anagen phase and increases follicle size. In a 48-week RCT comparing 5% vs. 2% vs. Placebo, 45% of men using 5% minoxidil were rated as having moderate-to-dense regrowth vs. 7% placebo (Olsen et al., JAAD 2002). Apply 1 mL twice daily to a dry scalp. Foam formulations have equivalent efficacy and may improve adherence.

Oral minoxidil 2.5-5 mg daily is off-label but increasingly prescribed for men who prefer oral dosing. A 24-week RCT (N=90) showed oral minoxidil 5 mg produced significantly greater vertex hair count increases than topical 5% (Ramos et al., JAAD 2020). Watch for peripheral edema and hypertrichosis.

Procedural and Combination Approaches

Platelet-rich plasma (PRP): Autologous growth factors injected into the scalp; a 2019 meta-analysis of 11 RCTs (N=262) in the International Journal of Molecular Sciences found significant increases in hair density and thickness vs. Controls. Sessions are typically monthly for three months, then quarterly.

Hair transplant surgery: Follicular unit excision (FUE) or follicular unit transplantation (FUT) moves DHT-resistant occipital follicles to thinning areas. Best outcomes occur when medical therapy is continued post-transplant to preserve native hairs.

Combining finasteride and minoxidil produces greater efficacy than either drug alone. A 12-month RCT (N=450) found the combination resulted in 2.3x greater hair count improvement vs. Finasteride monotherapy (Hu et al., Dermatologic Therapy 2015).

Female Pattern Hair Loss (Androgenetic Alopecia in Women)

Female pattern hair loss (FPHL) presents differently than MPHL. Diffuse thinning at the central part with preservation of the frontal hairline is the hallmark, graded on the Ludwig scale (I to III). Androgen sensitivity plays a role, but many women with FPHL have normal serum androgens, suggesting additional pathways including prostaglandin and Wnt/beta-catenin signaling.

Hormonal Evaluation

Before starting treatment, clinicians should rule out treatable hormonal causes. The Endocrine Society guidelines recommend measuring total and free testosterone, DHEA-S, prolactin, thyroid-stimulating hormone (TSH), and ferritin in women presenting with diffuse hair loss. Ferritin below 30 ng/mL may contribute to shedding independent of iron-deficiency anemia.

FDA-Approved and Off-Label Options for Women

Minoxidil 2% topical: The only FDA-approved topical for FPHL. Apply 1 mL twice daily. A 32-week RCT (N=256) showed 2% minoxidil produced significantly greater increase in hair count than placebo (P<0.01) (DeVillez et al., JAAD 1994).

Minoxidil 5% topical foam: FDA-approved for once-daily use in women. Shown to produce equivalent hair count gains to 2% twice-daily with a simpler regimen.

Spironolactone 25-200 mg daily: An off-label aldosterone antagonist that reduces adrenal androgen production and blocks androgen receptors in the follicle. A retrospective study of 1,006 women (published in JAAD 2017) found 74.6% reported subjective improvement in hair density after 12 months at mean dose 100 mg/day. Not recommended during pregnancy.

Finasteride 1-2.5 mg daily is off-label in women but used in post-menopausal women or those on reliable contraception. A 12-month RCT (N=37 post-menopausal women) found finasteride 1 mg produced significant improvement in vertex hair density vs. Placebo (Price et al., JAAD 2000).

Low-level laser therapy (LLLT) devices cleared by the FDA (e.g., 650 nm, 272 diodes for 25 minutes every other day) may augment topical treatment, particularly in women reluctant to take systemic medications.

Telogen Effluvium: Temporary Shedding After a Trigger

Telogen effluvium (TE) occurs when a physiological stressor prematurely shifts a large proportion of anagen hairs into the telogen (resting) phase. The hair cycle is roughly 100 days from telogen entry to shedding, so diffuse loss typically appears 2-4 months after the inciting event.

Common Triggers

• High fever or acute illness (including COVID-19)
• Major surgery or general anesthesia
• Childbirth (postpartum effluvium)
• Crash dieting or rapid weight loss (>15 lb over 3 months)
• Iron deficiency, thyroid dysfunction, or protein malnutrition
• Psychological stress sustained over months

A 2021 cohort study of 296 post-COVID-19 patients found 22% reported significant hair shedding at 6-month follow-up, consistent with telogen effluvium rather than direct follicular damage (Raveendran et al., International Journal of Dermatology 2021).

Diagnosis and Recovery

The pull test is a simple bedside tool. Grasping 40-60 hairs and pulling firmly in one motion yields more than six hairs in active TE. A trichogram showing more than 25% telogen hairs confirms the diagnosis. Scalp biopsy is reserved for chronic cases (>6 months) where androgenetic alopecia or cicatricial alopecia must be excluded.

Recovery is the rule in acute TE once the trigger resolves. Most patients see baseline density restored within 6-9 months without specific pharmacotherapy. Optimize ferritin above 70 ng/mL, correct thyroid abnormalities, and ensure dietary protein intake of at least 1.2 g/kg/day. Topical minoxidil 2-5% may accelerate regrowth in patients with prolonged shedding, though evidence is based on clinical experience rather than dedicated TE RCTs.

The HealthRX TE Triage Protocol:

1. Confirm trigger and timing (event to shedding lag of 2-4 months)
2. Lab panel: CBC, ferritin, TSH, free T4, comprehensive metabolic panel, total/free testosterone (women)
3. Correct deficiencies aggressively before labeling shedding as "idiopathic"
4. Reassess at 3 months; add topical minoxidil only if shedding persists beyond 4 months from trigger resolution
5. Refer to dermatology if no improvement by 9 months or if chronic TE pattern is suspected

Alopecia Areata: Autoimmune Patchy Hair Loss

Alopecia areata (AA) is a T-cell-mediated autoimmune condition targeting anagen follicles. CD8+ T-cells infiltrate the follicular bulb, collapsing immune privilege and halting hair production. Lifetime prevalence is approximately 2% globally, with equal sex distribution. Disease ranges from small discrete patches (AA) to complete scalp loss (alopecia totalis) or loss of all body hair (alopecia universalis).

Clinical Features and Diagnosis

The classic finding is one or more smooth, oval, non-scarring patches of hair loss on the scalp, beard, or eyebrows. Exclamation-mark hairs (broken, tapered distally) at the patch border are pathognomonic. Nail pitting occurs in up to 66% of cases and can help confirm diagnosis when the scalp presentation is atypical.

Dermoscopy reveals yellow dots, black dots, broken hairs, and short vellus hairs. Scalp biopsy shows a dense peribulbar lymphocytic infiltrate described as a "swarm of bees" pattern.

Treatment Options by Disease Severity

Mild-to-moderate AA (less than 50% scalp involvement):

Intralesional triamcinolone acetonide (ILK) at 5-10 mg/mL injected every 4-6 weeks is the AAD first-line recommendation for adults. A systematic review of 13 studies found response rates of 63-97% in localized AA with ILK (Alkhalifah et al., JAAD 2010). Maximum dose per session is 20 mg to minimize adrenal suppression risk.

Topical minoxidil 5% twice daily is often added as adjunctive therapy to stimulate regrowth in treated patches.

Severe AA (more than 50% scalp involvement or alopecia totalis/universalis):

Baricitinib (Olumiant) became the first FDA-approved systemic treatment for severe AA in June 2022. This JAK1/JAK2 inhibitor targets the interferon-gamma and interleukin-15 signaling pathways that drive follicular immune attack. In the BRAVE-AA1 trial (N=654), 38.8% of patients on baricitinib 4 mg achieved a SALT score of 20 or less (meaning at least 80% scalp coverage) at week 36, vs. 3.3% with placebo (P<0.001) (King et al., NEJM 2022). The 2 mg dose achieved this threshold in 22.8% of patients.

Ritlecitinib (Litfulo) 50 mg daily received FDA approval for AA in June 2023 for patients aged 12 and older. In the ALLEGRO phase 2b/3 trial (N=718), 23.4% of patients achieved SALT <20 at week 24 vs. 1.6% placebo (Shapiro et al., NEJM 2023).

Topical ruxolitinib (Opzelura) 1.5% cream is FDA-approved for mild-to-moderate AA; patients apply it twice daily to affected areas up to 30 cm squared.

Screening before JAK inhibitor initiation must include TB testing (QuantiFERON-TB Gold), hepatitis B and C serology, lipid panel, and CBC with differential per FDA prescribing information.

Comparing Hair Loss Types: A Clinical Quick Reference

| Feature | MPHL/FPHL | Telogen Effluvium | Alopecia Areata | |---|---|---|---| | Pattern | Patterned (Hamilton/Ludwig) | Diffuse | Patchy, any site | | Scarring | No | No | No | | Onset | Gradual, years | Acute, weeks-months | Rapid, days-weeks | | Pull test | Negative (usually) | Positive (>6 hairs) | Positive at patch margin | | Reversible | Partial with treatment | Yes, most cases | Variable | | Key blood test | Hormones, ferritin | Ferritin, TSH, CBC | Autoimmune screen optional | | First-line Rx | Finasteride, minoxidil | Correct trigger, nutrition | Triamcinolone ILK, JAK inhibitors |